WebNov 24, 2024 · Hairy cell leukemia variant (HCLv) is a distinct subtype of B-cell leukemia that shares morphologic features with classic HCL but is biologically distinct; it lacks … WebMay 22, 2024 · Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell …
Hairy Cell Leukemia: Symptoms, Cause, Treatment - WebMD
WebMay 26, 2024 · 7003 Background: Single-agent purine analog therapy, usually cladribine, has been the standard 1st-line therapy of hairy cell leukemia (HCL) for ~30 years. Relapse is attributed to minimal residual disease (MRD) persisting despite complete remission (CR). Rituximab can clear MRD, but there are no long-term data for how frequently and for how … WebJun 24, 2024 · Hairy cell leukemia (HCL) is a rare chronic B-cell leukemia. 1-3 The term HCL encompasses both the classic (cHCL) and variant (vHCL) forms, which are now recognized by the World Health Organization to be biologically distinct entities. 4 cHCL carries the BRAF p.V600E mutation and has excellent long-term outcomes in the … help with maths worksheets
CLL & PCD & PH&G - EBMT
WebChihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol 2024 ;38: ... WebMay 4, 2024 · Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang H-W, Zhou H, et al. Randomized Phase II Study of first-line Cladribine with concurrent or delayed … Webrituximab as an initial therapy option for hairy cell leukemia. This is a category 2A, preferred recommendation. Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized … help with mayo clinic sign in